Peficitinib
A Janus kinase inhibitor used in the treatment of rheumatoid arthritis
| Peficitinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Peficitinib is a Janus kinase inhibitor (JAK inhibitor) used in the treatment of rheumatoid arthritis. It is an orally administered medication that works by inhibiting the activity of Janus kinase enzymes, which play a key role in the inflammatory process associated with rheumatoid arthritis.
Mechanism of Action[edit | edit source]
Peficitinib functions by selectively inhibiting the activity of Janus kinase enzymes, particularly JAK1 and JAK3. These enzymes are involved in the signaling pathways of various cytokines and growth factors that are crucial for the immune response and inflammation. By blocking these pathways, peficitinib reduces the inflammatory response and alleviates the symptoms of rheumatoid arthritis.
Clinical Use[edit | edit source]
Peficitinib is primarily used for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to or are intolerant to other disease-modifying antirheumatic drugs (DMARDs). It is administered orally, providing a convenient option for patients compared to injectable therapies.
Side Effects[edit | edit source]
Common side effects of peficitinib include upper respiratory tract infections, headache, and increased liver enzymes. Serious side effects may include infections, gastrointestinal perforations, and hematologic abnormalities such as anemia and neutropenia. Patients on peficitinib require regular monitoring for these potential adverse effects.
Development and Approval[edit | edit source]
Peficitinib was developed by Astellas Pharma and has been approved for use in several countries for the treatment of rheumatoid arthritis. Its development involved extensive clinical trials to establish its efficacy and safety profile.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
